The first participant has been enrolled in a Phase 2 clinical trial evaluating the safety and efficacy of GDC-9545 in combination with palbociclib as an investigational treatment for postmenopausal women with estrogen receptor (ER)-positive and HER2-negative untreated early breast cancer. “The initiation of enrolment is an important milestone as we aim to better understand the activity and safety of this therapy in early stage breast cancer,” Sara Hurvitz, MD, medical director of the Jonsson Comprehensive Cancer Center Clinical Research Unit,…
You must be logged in to read/download the full post.
The post Clinical Trial Testing Estrogen Receptor Degrader GDC-9545 Enrolls First Participant appeared first on BioNewsFeeds.